Journal September 16, 2026 6 min read

Sermorelin vs GHRP-6: what the research actually compares

A comparison of sermorelin and GHRP-6 on what each is, what published work measured, where the evidence is stronger, and what remains unknown.

peptides-pro Editorial

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal segment of growth hormone-releasing hormone (GHRH), classified as a GHRH analogue. GHRP-6 (growth hormone-releasing peptide-6, also known as growth hormone-releasing hexapeptide) is a synthetic six-amino-acid peptide classified as a growth hormone secretagogue and a ghrelin receptor agonist. Both compounds act on the growth hormone (GH)–insulin-like growth factor-1 (IGF-1) axis, but through distinct receptor families: sermorelin binds the GHRH receptor, while GHRP-6 binds the ghrelin receptor (GHS-R1a).

The published literature on these two compounds differs in scope and model systems, and the evidence base for each is not symmetrical.

Research Studies

Sermorelin and the GH-IGF-1 axis in clinical and self-administration contexts

Sermorelin is listed among GHRH analogues encountered in clinical practice and online self-administration protocols intended to modulate the GH-IGF-1 axis [5]. The same review identifies GHRP-6 as a growth hormone secretagogue within the same broad category of performance-enhancing peptides marketed as research compounds [5]. This source does not report comparative efficacy data between the two compounds; it describes the landscape of agents and the gap between clinical evidence and patient self-administration.

Sermorelin and liver fat: evidence from a related GHRH analogue

A randomized, double-blind, placebo-controlled Phase II study is evaluating whether daily subcutaneous tesamorelin, a GHRH analogue, reduces liver fat in adults with fatty liver disease over 52 weeks, with liver fat quantified by MRI-proton density fat fraction and safety monitoring including glucose metrics and IGF-1 [6]. This trial concerns tesamorelin, not sermorelin, and no results are reported in the available evidence. It is included here because it represents the type of controlled clinical design used for GHRH analogues; it does not provide data on sermorelin itself.

GHRP-6 and post-infarct ventricular remodeling in rats

In a rat model of permanent coronary ligation, GHRP-6 was administered at 0.4 mg/kg, a dose previously determined as the minimum effective dose for enhancing inotropy in healthy rats. Infarcted rats treated with GHRP-6 for 7 days were compared with saline-treated infarcted controls and sham-operated rats, with echocardiographic assessment on day 7. The study reported that GHRP-6 ameliorated post-infarct ventricular remodeling and systolic dysfunction [1].

GHRP-6 and endocrine and immune responses in Sparus aurata

In gilthead sea bream (Sparus aurata), GHRP-6 included in aquafeed at 500 µg/kg of feed was assessed for effects on endocrine and immune responses following Incomplete Freund's adjuvant (IFA) treatment. After 97 days, fish were injected intraperitoneally with saline or IFA, and samples were collected [2]. The study examined the ghrelin analog GHRP-6 as an immunomodulatory feed additive in aquaculture.

GHRP-6 and locomotor activity during acute nicotine withdrawal in rats

Male and female Wistar rats were exposed to intraperitoneal nicotine (2 mg/kg) or saline twice daily for 7 days, then underwent acute nicotine withdrawal. Ghrelin and GHRP-6 were administered, and horizontal and vertical activity were measured. The study found that changes in locomotor activity during acute nicotine withdrawal could be attenuated by ghrelin and GHRP-6 [3]. Both peptides act through the same receptor in this context.

GHRP-6 and human oocyte maturation in vitro

In an experimental study, 240 human germinal vesicle oocytes were cultured in varying concentrations of GHRP-6, a ghrelin hormone agonist, to determine the most effective concentration in in vitro maturation (IVM) culture media. Maturation rates were assessed [8]. This work concerns oocyte maturation in culture, not systemic administration.

GHRP-6 and food intake in broiler chickens

In broiler chickens, intracerebroventricular injection of LEAP-2 and its interaction with cannabinoid and ghrelin systems was studied across four experiments. One experiment used (D-Lys-3)-GHRP-6 at 0.5 nmol as a ghrelin receptor antagonist to probe food intake [7]. This study examines GHRP-6 as a pharmacological tool in a avian model, not as a therapeutic agent.

GHRP-6 in acute lung injury and acute kidney injury models

In a model of acute lung injury and its progression to interstitial fibrosis, GHRP-6 was reported to ameliorate injury [9]. In a separate study, a GHRP-6 hydrogel was investigated for acute kidney injury therapy via metabolic regulation of renal tubular epithelial cells [10]. These findings are reported in the respective papers; they are noted here as part of the GHRP-6 literature but are not the focus of this comparison.

GHRP-6 and antiviral activity in fish

GHRP-6 was evaluated for activity against nervous necrosis virus (NNV) infection in fish, with the peptide described as a ghrelin analog with growth-promoting and immunomodulatory activities in several fish species [11]. This is a non-mammalian antiviral context.

Comparative summary of evidence

Feature	Sermorelin	GHRP-6
Class	GHRH analogue	GH secretagogue / ghrelin receptor agonist
Receptor family	GHRH receptor	Ghrelin receptor (GHS-R1a)
Identifiers in evidence	29-amino-acid peptide	Six-amino-acid peptide
Human clinical trial data in evidence	None for sermorelin; a related GHRH analogue (tesamorelin) is under Phase II study [6]	None
Animal models in evidence	None	Rat cardiac, rat behavioral, chicken food intake, fish immune/antiviral [1][2][3][7][11]
In vitro human data in evidence	None	Human oocyte maturation [8]
Case report in evidence	None	None directly; a case report describes a long-term GH user with osteophytic dysphagia [4]

Where the evidence is stronger for one compound

The evidence block contains multiple primary studies on GHRP-6 across cardiovascular, behavioral, aquaculture, reproductive, and antiviral models [1][2][3][7][8][9][10][11]. For sermorelin, the evidence block contains no primary study reporting measured outcomes; sermorelin appears only in a review of performance-enhancing peptides [5]. A clinical trial of tesamorelin, a different GHRH analogue, is registered but without results [6]. Therefore, within the supplied evidence, the published work measured more outcomes for GHRP-6 than for sermorelin.

What is simply not known

No study in the evidence block directly compares sermorelin and GHRP-6 in the same model or population. No human clinical outcome data for sermorelin are provided. No human clinical outcome data for GHRP-6 are provided. The long-term safety of either compound in humans is not addressed by the evidence. The case report of a 62-year-old male long-term growth hormone user with anterior cervical osteophyte-related dysphagia [4] concerns growth hormone, not sermorelin or GHRP-6, and cannot be attributed to either peptide. The evidence does not establish equivalence, superiority, or interchangeability between the two compounds.

If you are reading this for personal health reasons

The materials described here are sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.